Background

Canada’s Drug Agency (CDA-AMC) is developing its strategic plan to set a refreshed direction for the organization.

Over the past several years, we have been on a journey of growth and change, and have now transitioned to become CDA-AMC. The organization’s current (2022–2025) strategic plan has served as a bold vision guiding our activity in shaping future-ready health systems. We redesigned and launched the Post-Market Drug Evaluation program, led work with a multidisciplinary panel of experts to develop a prototype potential national formulary, and are actively involved in supporting the Drugs for Rare Diseases Strategy. We have also focused — and continue to focus —on our commitment to our guiding principles (including inclusion, diversity, equity, accesibility, and reconciliation), and improving how we work with and engage our partners and key collaborators (including provincial and territorial representatives, industry, patients, and others).

Developing our new 3-year strategic plan offers an opportunity for us to reflect on our growing role in the drug system through building upon our existing strengths in pharmaceutical reviews, as well as our expanded focus in the medical devices, clinical interventions, and health system optimization spaces while reflecting our new and expanded roles in Canada’s health care ecosystem.

This survey aims to gather your thoughts on the organization’s current and future strategic direction, the most significant opportunities for leadership and impact, and what it will take for the organization to be successful in our work ahead.

This survey should take approximately 15 minutes to complete. Please note that your participation in this survey is voluntary; you may choose not to participate, skip a question, or exit the survey at any time.

Any information that can identify you will be treated as confidential; only the CDA-AMC strategic planning team will have access to the full survey dataset, and any quotes will not be directly attributed to you or your organization.

If you have any other questions about this survey or CDA-AMC's strategic planning process, please email strategyplanning@CDA-AMC.ca

Question Title

* Consent
Please make a selection from 1 of the following options.
Clicking on the “Agree” button indicates that:
  • you have read the aforementioned information
  • you voluntarily agree to participate
  • you authorize CDA-AMC to use the information provided by you for the purpose stated in this form.
If you do not wish to participate in the survey, please decline participation by clicking on the “Disagree” button.

 
11% of survey complete.

T